Skip to content
Companies

Modulate Bio

Small-molecule drugs for essential tremor and epilepsy

Raised to date

$785K

of $1M offered across 1 Form D filing

Still open
$215K
Investors
10
Last filed
Apr 7, 2026

About

Modulate Bio Inc. is a preclinical neuroscience drug discovery company based at the Pagliuca Harvard Life Lab in Allston, Massachusetts. It develops small-molecule GABAA positive allosteric modulators designed to restore healthy brain receptor function without overactivating it. Its lead program targets Essential Tremor, with epilepsy in close pursuit and anxiety and rare neurological diseases as later indications. The company has reported in vivo proof-of-concept in mice and says it is close to naming a development candidate for Essential Tremor.

A discovery platform for subtype-selective GABAA positive allosteric modulators that aims for precise receptor control, seeking efficacy on validated CNS targets while avoiding the sedation and tolerability problems that limit existing GABAA drugs.

Funding

  • Option to acquireFiled Apr 7, 2026Form D/A
    $785K/ $1M

Product

Essential Tremor program

Preclinical small-molecule therapeutic program

A preclinical small-molecule program built on the company's GABAA positive allosteric modulator platform, targeting Essential Tremor. The company reports in vivo proof-of-concept in mice and says it is approaching development candidate selection.

  • Novel, differentiated GABAA positive allosteric modulators
  • Subtype selectivity for precise control of receptor activation
  • Validated biological targets with translational assays

Built for

Patients with Essential Tremor, epilepsy and other CNS disorders, reached through neurologists and, commercially, through biopharma partners or acquirers

People on file